Dr. Jie Ding joined InxMed in January 2023. He spent more than twenty years in the pharmaceutical industry with experiences across the entire new medicine development spectrum from preclinical discovery research to late phase clinical development with multiple successful global NDA and sNDA registrations mainly in the oncology area. Dr. Ding started his career at GlaxoSmithKline (2002~2016). During 2007~2011, Dr. Ding was the lead Principle Statistician for the VEGF inhibitor Pazopanib in the Advanced RCC indication (approved by FDA in 2009) and several other indications including HCC, Thyroid, Sarcoma, etc. In 2016, Dr. Ding joined Merck & Co. (MSD), and his work directly led to FDA accelerated approval of Keytruda in the MSI-High Pan tumor indication (2017), the first ever pan tumor agnostic indication in history. From 2017 to 2021, Dr. Ding returned to Beijing and was Sr. Director and head of Biostatistics & Research Decision Science – Asia Pacific (BARDS-AP) at Merck (MSD). He and his team of 50+ statisticians and programmers in BARDS-AP successfully supported multiple NDA and sNDA including Keytruda and other medicines in the US, EU and Asia Pacific regions (China and Japan) in a little over three years. From 2021 to 2022, Dr. Ding was the Executive Director and head of Biostatistics at the Sumitomo Pharma Oncology in Cambridge, Massachusetts. Dr. Ding holds a Bachelor’s degree in Mathematics from Nankai University and a Ph.D. degree in Statistics from Temple University.